AB 1682: Health care coverage: scalp cooling.
- Session Year: 2025-2026
- House: Assembly
- Latest Version Date: 2026-09-27
Current Status:
Passed
(2026-09-27: Chaptered by Secretary of State - Chapter 541, Statutes of 2026.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires coverage by health care service plans and health insurers for various screening and treatment services with respect to cancer.
This bill would require a large group health care service plan contract or health insurance policy that is issued, amended, or renewed on and after January 1, 2027, to provide coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. The bill would define scalp cooling for these purposes. Because a violation of these provisions with respect to a health care service plan would be a crime, this bill would impose a state-mandated local program.
Existing law also provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services pursuant to a schedule of benefits, including various cancer screenings and benefits relating to cancer treatment.
Subject to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained, this bill would expand the Medi-Cal schedule of benefits to include scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. The bill would subject scalp cooling to utilization controls and medical necessity.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires coverage by health care service plans and health insurers for various screening and treatment services with respect to cancer.
This bill would require a large group health care service plan contract or health insurance policy that is issued, amended, or renewed on and after January 1, 2027, to provide coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. The bill would define scalp cooling for these purposes. Because a violation of these provisions with respect to a health care service plan would be a crime, this bill would impose a state-mandated local program.
Existing law also provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services pursuant to a schedule of benefits, including various cancer screenings and benefits relating to cancer treatment.
Subject to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained, this bill would expand the Medi-Cal schedule of benefits to include scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. The bill would subject scalp cooling to utilization controls and medical necessity.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires coverage by health care service plans and health insurers for various screening and treatment services with respect to cancer.
This bill would require a large group health care service plan contract or health insurance policy that is issued, amended, or renewed on and after January 1, 2027, to provide coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. The bill would also require a small group health care service plan contract or health insurance policy that is issued, amended, or renewed on or after January 1, 2027, to offer that coverage, as specified. The bill would define scalp cooling for these purposes. Because a violation of these provisions with respect to a health care service plan would be a crime, this bill would impose a state-mandated local program.
Existing law also provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services pursuant to a schedule of benefits, including various cancer screenings and benefits relating to cancer treatment.
Subject to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained, this bill would expand the Medi-Cal schedule of benefits to include scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. The bill would subject scalp cooling to utilization controls and medical necessity.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires coverage by health care service plans and health insurers for various screening and treatment services with respect to cancer.
This bill would require a health care service plan contract or health insurance policy, except as specified, that is issued, amended, delivered, or renewed on or after January 1, 2027, to provide coverage for scalp cooling, as defined, as prescribed by a health care provider in connection with chemotherapy for persons with cancer.This bill would require a large group health care service plan contract or health insurance policy that is issued, amended, or renewed on and after January 1, 2027, to provide coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. The bill would also require a small group health care service plan contract or health insurance policy that is issued, amended, or renewed on or after January 1, 2027, to offer that coverage, as specified. The bill would define scalp cooling for these purposes. Because a violation of these provisions with respect to a health care service plan would be a crime, this bill would impose a state-mandated local program.
Existing law also provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services pursuant to a schedule of benefits, including various cancer screenings and benefits relating to cancer treatment.
Subject to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained, this bill would expand the Medi-Cal schedule of benefits to include scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer. when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. The bill would subject scalp cooling to utilization controls and medical necessity.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires coverage by health care service plans and health insurers for various screening and treatment services with respect to cancer.
This bill would require a health care service plan contract or health insurance policy, except as specified, that is issued, amended, delivered, or renewed on or after January 1, 2027, to provide coverage for scalp cooling, as defined, as prescribed by a health care provider in connection with chemotherapy for persons with cancer. Because a violation of these provisions with respect to a health care service plan would be a crime, this bill would impose a state-mandated local program.
Existing law also provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services pursuant to a schedule of benefits, including various cancer screenings and benefits relating to cancer treatment.
Subject to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained, this bill would expand the Medi-Cal schedule of benefits to include scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)A large group health care service plan contract issued, amended, or renewed on and after January 1, 2027, shall provide coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used.
(b)Coverage required by this section may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an enrollee than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same contract.
(c)For purposes of this section, scalp cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether those products are described as cold cap therapy or similar terminology.
(d)(1)This section shall not apply to specialized health care service plans.
(2)This section shall not apply to a Medi-Cal managed care plan contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000) or Chapter 8 (commencing with Section 14200) of Part 3 of Division 9 of the Welfare and Institutions Code. A Medi-Cal managed care plan contract shall instead be subject to Section 14132.65 of the Welfare and Institutions Code.
SEC. 2.Section 10123.811 is added to the Insurance Code, to read:10123.811.(a)A large group health insurance policy issued, amended, or renewed on and after January 1, 2027, shall provide coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used.
(b)Coverage required by this section may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an insured than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same policy.
(c)For purposes of this section, scalp cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether such products are described as cold cap therapy or similar terminology.
(d)This section shall not apply to a specialized health insurance policy.
SEC. 3.Section 14132.65 is added to the Welfare and Institutions Code, to read:14132.65.(a)Scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used, is a covered benefit and shall be subject to utilization controls and medical necessity.
(b)For purposes of this section, scalp cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) that is applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include any non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether such products are described as cold cap therapy or similar terminology.
(c)This section shall be implemented in a manner consistent with federal law and only to the extent any necessary federal approvals have been obtained and federal financial participation is available and not otherwise jeopardized.
(d)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, and make specific this section by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions, without taking any further regulatory action.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A large group health care service plan contract issued, amended, or renewed on and after January 1, 2027, shall provide coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used.
(b)Coverage required by this section may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an enrollee than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same contract.
(c)For purposes of this section, scalp cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether those products are described as cold cap therapy or similar terminology.
(d)(1)This section shall not apply to specialized health care service plans.
(2)This section shall not apply to a Medi-Cal managed care plan contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000) or Chapter 8 (commencing with Section 14200) of Part 3 of Division 9 of the Welfare and Institutions Code. A Medi-Cal managed care plan contract shall instead be subject to Section 14132.65 of the Welfare and Institutions Code.
SEC. 2.Section 10123.811 is added to the Insurance Code, to read:10123.811.(a)A large group health insurance policy issued, amended, or renewed on and after January 1, 2027, shall provide coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used.
(b)Coverage required by this section may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an insured than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same policy.
(c)For purposes of this section, scalp cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether such products are described as cold cap therapy or similar terminology.
(d)This section shall not apply to a specialized health insurance policy.
SEC. 3.Section 14132.65 is added to the Welfare and Institutions Code, to read:14132.65.(a)Scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used, is a covered benefit and shall be subject to utilization controls and medical necessity.
(b)For purposes of this section, scalp cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) that is applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include any non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether such products are described as cold cap therapy or similar terminology.
(c)This section shall be implemented in a manner consistent with federal law and only to the extent any necessary federal approvals have been obtained and federal financial participation is available and not otherwise jeopardized.
(d)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, and make specific this section by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions, without taking any further regulatory action.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A large group health care service plan contract issued, amended, or renewed on and after January 1, 2027, shall provide coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used.
(b)(1)A small group health care service plan contract issued, amended, or renewed on and after January 1, 2027, shall offer coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. If coverage is provided to an enrollee pursuant to this subdivision, the level of coverage provided shall be consistent with the level of coverage provided under subdivision (a).(2)This subdivision shall not be construed to require a small group health care service plan contract to provide coverage for scalp cooling. (c)(b)Coverage required by this section may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an enrollee than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same contract.
(d)(c)For purposes of this section, scalp cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether those products are described as cold cap therapy or similar terminology.
(e)(d)(1)This section shall not apply to specialized health care service plans.
(2)This section shall not apply to a Medi-Cal managed care plan contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000) or Chapter 8 (commencing with Section 14200) of Part 3 of Division 9 of the Welfare and Institutions Code. A Medi-Cal managed care plan contract shall instead be subject to Section 14132.65 of the Welfare and Institutions Code.
SEC. 2.Section 10123.811 is added to the Insurance Code, to read:10123.811.(a)A large group health insurance policy issued, amended, or renewed on and after January 1, 2027, shall provide coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used.
(b)(1)A small group health insurance policy issued, amended, or renewed on and after January 1, 2027, shall offer coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. If coverage is provided to an insured pursuant to this subdivision, the level of coverage provided shall be consistent with the level of coverage provided under subdivision (a).(2)This subdivision shall not be construed to require a small group health insurance policy to provide coverage for scalp cooling. (c)(b)Coverage required by this section may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an insured than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same policy.
(d)(c)For purposes of this section, scalp cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether such products are described as cold cap therapy or similar terminology.
(e)(d)This section shall not apply to a specialized health insurance policy.
SEC. 3.Section 14132.65 is added to the Welfare and Institutions Code, to read:14132.65.(a)Scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used, is a covered benefit and shall be subject to utilization controls and medical necessity.
(b)For purposes of this section, scalp cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) that is applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include any non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether such products are described as cold cap therapy or similar terminology.
(c)This section shall be implemented in a manner consistent with federal law and only to the extent any necessary federal approvals have been obtained and federal financial participation is available and not otherwise jeopardized.
(d)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, and make specific this section by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions, without taking any further regulatory action.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A large group health care service plan contract issued, amended, or renewed on and after January 1, 2027, shall provide coverage for scalp cooling, as when prescribed by a health care provider in connection with chemotherapy for persons with cancer. to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used.
(b)(1)A small group health care service plan contract issued, amended, or renewed on and after January 1, 2027, shall offer coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. If coverage is provided to an enrollee pursuant to this subdivision, the level of coverage provided shall be consistent with the level of coverage provided under subdivision (a).
(2)This subdivision shall not be construed to require a small group health care service plan contract to provide coverage for scalp cooling.
(b)(c)Coverage required by this section may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an enrollee than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same contract.
(c)(d)For purposes of this section, scalp cooling is defined as cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether those products are described as cold cap therapy or similar terminology.
(d)(e)(1)This section shall not apply to specialized health care service plans.
(2)This section shall not apply to a Medi-Cal managed care plan contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000) or Chapter 8 (commencing with Section 14200) of Part 3 of Division 9 of the Welfare and Institutions Code. A Medi-Cal managed care plan contract shall instead be subject to Section 14132.65 of the Welfare and Institutions Code.
SEC. 2.Section 10123.811 is added to the Insurance Code, to read:10123.811.(a)A large group health insurance policy issued, amended, or renewed on and after January 1, 2027, shall provide coverage for scalp cooling, as when prescribed by a health care provider in connection with chemotherapy for persons with cancer. to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used.
(b)(1)A small group health insurance policy issued, amended, or renewed on and after January 1, 2027, shall offer coverage for scalp cooling, when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. If coverage is provided to an insured pursuant to this subdivision, the level of coverage provided shall be consistent with the level of coverage provided under subdivision (a).
(2)This subdivision shall not be construed to require a small group health insurance policy to provide coverage for scalp cooling.
(b)(c)Coverage required by this section may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an insured than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same policy.
(c)(d)For purposes of this section, scalp cooling is defined as cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy induced chemotherapy-induced alopecia (hair loss). Scalp cooling does not include nonFDA-cleared cold caps or any nonFDA-cleared scalp cooling products, regardless of whether such products are described as cold cap therapy or similar terminology.
(d)(e)This section shall not apply to a specialized health insurance policy.
SEC. 3.Section 14132.65 is added to the Welfare and Institutions Code, to read:14132.65.(a)Scalp cooling, as when prescribed by a health care provider in connection with chemotherapy for persons with cancer, to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used, is a covered benefit under the Medi-Cal program. and shall be subject to utilization controls and medical necessity.
(b)Coverage required by this section may be subject to copayments or deductibles, provided that the copayments or deductibles applicable to scalp cooling are no less favorable to a beneficiary than the copayments or deductibles that apply to oncology supportive care services that are covered benefits under the Medi-Cal program. (c)(b)For purposes of this section, scalp cooling is defined as cooling means the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) that is applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy induced chemotherapy-induced alopecia (hair loss). Scalp cooling does not include any nonFDA-cleared cold caps or any nonFDA-cleared scalp cooling products, regardless of whether such products are described as cold cap therapy or similar terminology.
(d)(c)This section shall be implemented in a manner consistent with federal law and only to the extent any necessary federal approvals have been obtained and federal financial participation is available and not otherwise jeopardized.
(d)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, and make specific this section by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions, without taking any further regulatory action.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan contract issued, amended, or renewed on and after January 1, 2027, shall provide coverage for scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer.
(b)Coverage required by this section may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an enrollee than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same contract.
(c)For purposes of this section, scalp cooling is defined as the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Scalp cooling does not include non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether those products are described as cold cap therapy or similar terminology.
(d)This section shall not apply to specialized health care service plans.
SEC. 2.Section 10123.811 is added to the Insurance Code, to read:10123.811.(a)A health insurance policy issued, amended, or renewed on and after January 1, 2027, shall provide coverage for scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer.
(b)Coverage required by this section may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an insured than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same policy.
(c)For purposes of this section, scalp cooling is defined as the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy induced alopecia (hair loss). Scalp cooling does not include nonFDA-cleared cold caps or any nonFDA-cleared scalp cooling products, regardless of whether such products are described as cold cap therapy or similar terminology.
(d)This section shall not apply to a specialized health insurance policy.
SEC. 3.Section 14132.65 is added to the Welfare and Institutions Code, to read:14132.65.(a)Scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer, is a covered benefit under the Medi-Cal program.
(b)Coverage required by this section may be subject to copayments or deductibles, provided that the copayments or deductibles applicable to scalp cooling are no less favorable to a beneficiary than the copayments or deductibles that apply to oncology supportive care services that are covered benefits under the Medi-Cal program.
(c)For purposes of this section, scalp cooling is defined as the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy induced alopecia (hair loss). Scalp cooling does not include nonFDA-cleared cold caps or any nonFDA-cleared scalp cooling products, regardless of whether such products are described as cold cap therapy or similar terminology.
(d)This section shall be implemented in a manner consistent with federal law and only to the extent federal financial participation is available and not otherwise jeopardized.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Sep 27, 2026 | Chaptered by Secretary of State - Chapter 541, Statutes of 2026. |
| Sep 27, 2026 | Approved by the Governor. |
| Sep 3, 2026 | Enrolled and presented to the Governor at 4 p.m. |
| Aug 26, 2026 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 71. Noes 0. Page 6633.). |
| Aug 26, 2026 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 71. Noes 0.). |
| Aug 26, 2026 | In Assembly. Concurrence in Senate amendments pending. |
| Aug 26, 2026 | Read third time. Passed. Ordered to the Assembly. (Ayes 39. Noes 0. Page 5849.). |
| Aug 26, 2026 | Read third time. Passed. Ordered to the Assembly. (Ayes 39. Noes 0.). |
| Aug 24, 2026 | Read second time. Ordered to third reading. |
| Aug 21, 2026 | Read third time and amended. Ordered to second reading. |
| Aug 17, 2026 | Read second time. Ordered to third reading. |
| Aug 13, 2026 | Read second time and amended. Ordered returned to second reading. |
| Aug 13, 2026 | From committee: Amend, and do pass as amended. (Ayes 7. Noes 0.) (August 13). |
| Aug 3, 2026 | In committee: Referred to APPR. suspense file. |
| Jun 25, 2026 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 11. Noes 0.) (June 24). Re-referred to Com. on APPR. |
| Jun 10, 2026 | Referred to Com. on HEALTH. |
| May 28, 2026 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 27, 2026 | Read third time. Passed. Ordered to the Senate. (Ayes 67. Noes 1. Page 5446.) |
| May 27, 2026 | Read third time. Passed. Ordered to the Senate. (Ayes 67. Noes 1.) |
| May 27, 2026 | Read third time. Passed. Ordered to the Senate. |
| May 18, 2026 | Read second time. Ordered to third reading. |
| May 14, 2026 | From committee: Do pass. (Ayes 12. Noes 0.) (May 14). |
| May 6, 2026 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 22, 2026 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 14. Noes 0.) (April 21). Re-referred to Com. on APPR. |
| Feb 17, 2026 | Referred to Com. on HEALTH. |
| Feb 3, 2026 | From printer. May be heard in committee March 5. |
| Feb 2, 2026 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 26, 2026 | AB 1682 Hart Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 26, 2026 | Assembly 3rd Reading AB1682 Hart et al. By Rubio | Senate Floor |
Passed |
|
| Aug 13, 2026 | Do pass as amended | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 3, 2026 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 24, 2026 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 27, 2026 | AB 1682 Hart Assembly Third Reading | Assembly Floor |
Passed |
|
| May 14, 2026 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 21, 2026 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| America’s Health Insurance Plans | ** Against | |
| America'S Health Insurance Plans | ** Against | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| Association of LIfe and Health Insurance Companies | ** Against | |
| Association Of Northern California Oncologists | ** Support | |
| Biocom California | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Medical Association | ** Support | |
| California Small Business Association | ** Against | |
| CenCal Health | ** Support | |
| Cooler Heads Care | ** Support | |
| Cooler Heads Care, Inc. | ** Support | |
| Cottage Health | ** Support | |
| Five individuals | ** Support | |
| Health Access California | ** Support | |
| Medical Oncology Association Of Southern California | ** Support | |
| Oncology Nursing Society | ** Support | |
| Paxman US Inc. | ** Support | |
| Paxman US, Inc. | ** Support | |
| The Rapunzel Project | ** Support |
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1682
Author:(Hart)
As Amended Ver:August 21, 2026
Majority vote
SUMMARY
Requires a large-group health plan, health insurer, and the Medi-Cal program, to provide coverage for scalp cooling, as prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used. Requires cost-sharing for scalp cooling to be no less favorable to an enrollee than cost-sharing for oncology supportive care services. Defines "scalp cooling" as the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss).
Senate Amendments
- Limit commercial coverage to large-group plans and insurers.
- Strike copayment limitations in the Medi-Cal provisions of the bill. Clarify that Medi-Cal may subject scalp cooling to utilization controls and medical necessity.
COMMENTS
Each year, approximately 185,000 Californians receive a new cancer diagnosis. Chemotherapy — medication delivered intravenously to target rapidly dividing tumor cells — is used to treat many common solid tumor cancers, including breast, ovarian, uterine, lung, and sarcomas. Chemotherapy-induced alopecia is typically temporary; hair usually begins to regrow within weeks to months after treatment ends. Chemotherapy-induced alopecia typically begins two to four weeks after the start of treatment and is consistently among the most commonly reported and distressing side effects of cancer treatment. Unlike most other side effects, hair loss is visible to others, and patients may lose control over who knows they have cancer and when. Scalp cooling works by cooling the scalp before, during, and after chemotherapy infusion to reduce the amount of drug delivered to hair follicles, thereby aiming to reduce hair loss. FDA-cleared scalp cooling systems are automated, which allows cool fluid to circulate through the cap to maintain the desired temperature for long periods of time. Manual cold caps, by contrast, are stored in freezers or with dry ice and must be swapped out by hand throughout the infusion as they warm up. The FDA-cleared scalp cooling systems covered under this bill are marketed under the names DigniCap, Paxman, and Amma. This bill would require coverage for FDA-cleared automated scalp cooling systems; manual cold caps are excluded from the bill.
California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on essential health benefits, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP's purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Premium increases. An estimated 680 additional enrollees would receive scalp cooling under the provisions of this bill, resulting in overall premiums paid by employers and enrollees increasing by an estimated $4,010,000 annually.
- Medical effectiveness. CHBRP found strong evidence that FDA-cleared automated scalp cooling devices are effective in reducing chemotherapy-induced alopecia. Some evidence suggests that scalp cooling devices may be less effective for patients with different hair types, such as Black patients with curly hair. There is strong evidence indicating that scalp cooling does not raise the risk of scalp metastasis.
- Public health impacts. CHRBP determined that approximately 333 newly covered enrollees experiencing significantly less hair loss than they otherwise would have, which may reduce distress, anxiety, and self-image impacts associated with chemotherapy-induced alopecia. The long-term trajectory of this bill may depend on several interacting factors, including the pace of utilization growth relative to per-unit pricing, and the reduction in utilization of other services like medical wigs, cold caps, or mental health services that were not directly modeled in this analysis.
Office of Health Care Affordability (OHCA) cost targets. OHCA was established in 2022 in response to widespread cost-related access challenges across California. According to the California Health Care Foundation (CHCF), over half of Californians say they skip or delay health care due to costs. OHCA collects, analyzes, and publicly reports data on total health care expenditures and enforces spending targets. OHCA's spending targets are intended to reduce excess spending and slow health care spending growth. In April of 2024, OHCA approved a statewide cost growth target of 3.5% starting in 2025 and phasing down to 3% by 2029. Health care entities, including health plans and insurers, are subject to the statewide spending target and are subject to progressive enforcement if the entity's costs exceed the target. Some entities have raised concerns that new legislative insurance mandates will make it difficult for them to meet the established cost growth target.
Current law does not explicitly require OHCA to adjust the cost growth targets based on changes to state policy, such as insurance mandates, that may increase spending. However, it does require OHCA to consider state benefit mandates in its development and enforcement of cost growth targets. Specifically, when establishing cost growth target methodology, OHCA is required to review relevant state policy changes impacting covered benefits, provider reimbursement, and costs, among other factors. In addition, in enforcing cost growth targets, OHCA is required to consider factors that contribute to spending in excess of the applicable target, and the extent to which each entity has control over the applicable components of its cost targets.
According to the Author
This bill is a critical step toward improving supportive cancer care and ensuring that patients receiving chemotherapy can have access to medically necessary treatment. The author continues that scalp cooling is an FDA cleared, evidence-based therapy for chemotherapy-induced hair loss – yet insurance coverage remains inconsistent and unpredictable. The author notes that this leaves many patients with significant out-of-pocket costs during an already difficult time. The author concludes that by requiring California health plans and health insurers to cover scalp cooling when prescribed by a provider, this bill will remove major financial barriers and support patients' mental health by reducing treatment-related distress.
Arguments in Support
Cooler Heads Care writes in support of this bill, stating that hair loss is not simply cosmetic; for many patients, it represents loss of privacy, identity, and control during an already vulnerable time. Cooler Heads Care continues that in modern oncology care, there are supportive remedies available for nearly every major chemotherapy side effect, from medications that address nausea and vomiting to therapies that manage pain and fatigue, hair loss should be no different. Cooler Heads Care continues that demand for scalp cooling continues to increase as awareness expands and clinicians seek supportive care solutions that treat the whole person. Cooler Heads Care notes that despite its demonstrated benefit, cost for scalp cooling remains a barrier for many patients. Cooler Heads Care concludes that insurance coverage would significantly expand equitable access, ensuring that patients are not forced to forego this supportive therapy due to financial constraints.
Arguments in Opposition
A coalition letter from the Association of Life and Health Insurance Companies, the California Association of Health Plans, and America's Health Insurance Plans state that this bill is one of eleven health insurance mandate bills that they oppose this session on the principle that the bills will increase health insurance premiums, harming health care affordability, access, and flexibility for small businesses and individuals. The opposition notes that OHCA has established statewide health care spending growth target of 3%, which is being phased in at 3.5% for 2025 and 2026, 3.2% in 2027 and 2028, and 3% percent in 2029 and beyond. The opposition emphasizes that while OHCA is working to curb healthcare costs and ensure resources are allocated efficiently, adding new mandates could disrupt these efforts by driving up costs for insurers, employers, and consumers, making it difficult for health care entities to meet the established targets. The opposition concludes that at this moment, the state should focus on healthcare stability and affordability for all Californians.
FISCAL COMMENTS
According to the Senate Appropriations Committee, there are unknown, likely minor costs for the Department of Managed Health Care and the California Department of Insurance for state administration, and unknown ongoing General Fund costs, potentially tens of thousands, due to increased CalPERS plan premiums.
VOTES:
ASM HEALTH: 14-0-2
YES: Bonta, Addis, Aguiar-Curry, Ahrens, Caloza, Carrillo, Mark González, Johnson, Patel, Patterson, Rogers, Schiavo, Sharp-Collins, Stefani
ABS, ABST OR NV: Chen, Sanchez
ASM APPROPRIATIONS: 12-0-3
YES: Wicks, Hoover, Aguiar-Curry, Calderon, Caloza, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache
ABS, ABST OR NV: Dixon, Ta, Tangipa
ASSEMBLY FLOOR: 67-1-12
YES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Davies, Elhawary, Fong, Gabriel, Garcia, Gipson, Jeff Gonzalez, Mark González, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Johnson, Kalra, Krell, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Michelle Rodriguez, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
NO: DeMaio
ABS, ABST OR NV: Castillo, Chen, Dixon, Ellis, Flora, Gallagher, Hadwick, Lackey, Celeste Rodriguez, Sanchez, Ta, Tangipa
UPDATED
VERSION: August 13, 2026
CONSULTANT: Riana King / HEALTH / (916) 319-2097 FN: 0004128
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | AB 1682 |
THIRD READING
Bill No: AB 1682
Author: Hart (D), et al.
Amended: 8/21/26 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 11-0, 6/24/26
AYES: Weber Pierson, Valladares, Caballero, Durazo, Gonzalez, Grove, Menjivar, Padilla, Pérez, Rubio, Smallwood-Cuevas
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/13/26
AYES: Cervantes, Seyarto, Cabaldon, Dahle, Grayson, Richardson, Wahab
ASSEMBLY FLOOR: 67-1, 5/27/26 - See last page for vote
SUBJECT: Health care coverage: scalp cooling
SOURCE: Author
DIGEST:
This bill (1) requires large group health care service plan contracts or health insurance policies to provide coverage for scalp cooling as prescribed by a health care provider in connection with chemotherapy in which alopecia-inducing chemotherapeutic agents are used; and (2) expands the Medi-Cal schedule of benefits to include scalp cooling, subject to utilization controls and medical necessity.
Senate Floor Amendments of 8/21/2026 delete the requirement for small group health care service plan contracts and health insurance policies to offer scalp-cooling coverage when prescribed by a health care provider to reduce the incidence or severity of alopecia before, during, or after chemotherapy in which alopecia-inducing chemotherapeutic agents are used.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975; California Department of Insurance (CDI) to regulate health and other insurance; and the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [Health & Safety Code (HSC) §1340, et seq., Insurance Code (INS) §106, et seq., and Welfare & Institutions Code (WIC) §14000, et seq.]
- Requires an individual and small group health plan contracts and insurance policies to include at a minimum coverage for Essential Health Benefits (EHBs) pursuant to the Affordable Care Act (ACA), and as outlined below:
- Health benefits within the ten federally required categories identified in the ACA;
- Health benefits covered by the Kaiser Foundation Health Plan Small Group HMO 30 (Kaiser Small Group HMO), as this plan was offered during the first quarter of 2014, regardless of whether the benefits are specifically referenced in the evidence of coverage or in the contract or policy;
- Medically necessary basic health care services, as specified;
- Health benefits mandated to be covered pursuant to statutes enacted before December 31, 2011, as described; and,
- Health benefits covered by the plan or policy that are not otherwise required to be covered, as specified. [HSC §1367.005 and INS §10112.27]
- Defines “basic health care services” as physician services including consultation and referral, hospital inpatient services and ambulatory care services, diagnostic laboratory and therapeutic radiologic services, home health services, preventative health services, emergency health care services, including ambulance and ambulance transport services and out-of-area coverage (including those provided through the 911 emergency response system), and hospice care. [HSC §1345]
- Requires health plan contracts and insurance policies, except specialized plans and policies, to provide coverage for screening for, diagnosis of, and treatment for, breast cancer. [HSC §1367.6 and INS §10123.8]
This bill:
- Requires large group health plan contracts and insurance policies to cover scalp cooling as prescribed by a health care provider in connection with chemotherapy with alopecia-inducing chemotherapeutic agents.
- Requires Medi-Cal benefits to include scalp cooling as prescribed by a health care provider in connection with chemotherapy with alopecia-inducing chemotherapeutic agents, subject to utilization controls and medical necessity.
- Defines “scalp cooling” as the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Clarifies that “scalp cooling” does not include non-FDA-cleared scalp cooling products.
Comments
According to the author of this bill:
This bill is a critical step toward improving supportive cancer care and ensuring that patients receiving chemotherapy can have access to medically necessary treatment. Scalp cooling is an FDA-cleared, evidence-based therapy for chemotherapy-induced hair loss, but insurance coverage remains inconsistent and unpredictable. This leaves many patients to pay significant out-of-pocket costs during an already difficult time. By requiring California health plans and health insurers to cover scalp cooling when prescribed by a provider, this bill helps remove a major financial barrier and supports patients’ mental health.
Background
Chemotherapy-induced alopecia. According to a 2020 review in Current Oncology, chemotherapy-induced alopecia is the hair loss that occurs when the cytotoxic drugs in chemotherapy regimens kill rapidly proliferating cells, which, beyond cancerous cells, includes growing hair follicle cells. Because up to 90% of scalp hair follicles are in the growth phase at any given time, scalp hair loss within the first several weeks of chemotherapy initiation can be significant. According to the American Cancer Society, the likelihood of hair loss is dependent on the chemotherapy regimen prescribed. Chemotherapy-induced alopecia is generally reversible three to six months after cessation of chemotherapy, although the new hair may show different texture and color, and some patients experience no hair regrowth or only partial hair regrowth. The Current Oncology review highlights that chemotherapy-related hair loss has been shown to have a negative impact on patients’ self-esteem, body image, sexuality, and overall quality of life.
Scalp cooling. According to the American Cancer Society, scalp cooling works to prevent hair loss by restricting the blood flow to the scalp, which decreases the amount of chemotherapy drug that gets to the hair follicles. Scalp cooling is used before, during, and after each chemotherapy session. Scalp cooling is an established practice in oncology care; in 2022, the American Medical Association adopted a resolution supporting insurance coverage for scalp cooling and recently updated its billing codes for scalp cooling to Category 1, or permanent codes that reflect accepted procedures or services.
Scalp cooling can be performed with either manual cold caps or automated scalp cooling systems. According to the American Cancer Society, manual cold caps are manually cooled in a freezer or with dry ice and must be switched every 30 minutes to manually regulate the temperature and prevent the cap from warming. In contrast, automated scalp cooling devices automatically circulate a liquid or gel around a snug-fitting silicone cap to cool the scalp to a specific temperature. Three automated scalp cooling systems are available for patients: DigniCap, Paxman, and Amma. Medicare currently covers automated scalp cooling when performed with FDA-approved, automated scalp cooling systems, not manual cold caps. One 2024 meta-analysis examining the efficacy of automatic scalp-cooling devices and manual cooling products showed no significant differences in hair preservation on various chemotherapy regimens.
California Health Benefit Review Program (CHBRP) analysis. Key findings include:
- Coverage impacts and enrollees covered. This bill applies to all state-regulated health insurance. CHBRP estimates that 22.8 million Californians (60% of the state) have Medi-Cal or CDI- and DMHC-regulated insurance subject to this bill. Approximately 47% of Californians have plans already compliant with this bill. This bill would extend a scalp cooling benefit to the remaining 12 million enrollees.
- Medical effectiveness. There is strong evidence that FDA-cleared automated scalp cooling devices are effective in reducing chemotherapy-induced alopecia. Some evidence suggests that scalp cooling may be less effective for patients with different hair types, such as for Black patients with curly hair. There is strong evidence that scalp cooling does not raise the risk of scalp metastasis.
- Utilization. CHBRP estimates that 630 enrollees use scalp cooling to prevent chemotherapy-induced hair loss, 440 of which have coverage at baseline and 190 of which do not. This bill would result in 680 additional enrollees receiving scalp cooling therapy, 90 of which had coverage at baseline and would continue to have coverage, but with increased utilization due to an increase in availability and awareness. The remaining 590 additional enrollees are those who did not have coverage but would have coverage with the enactment of this bill.
- Medi-Cal. This bill includes Medi-Cal enrollees. Because Medi-Cal coverage generally does not include enrollee cost-sharing, those with Medi-Cal will not experience any change in the cost of utilizing the scalp cooling benefit.
- Impact on expenditures. CHBRP estimates that the average cost of scalp cooling per enrollee for a course of chemotherapy over a year is $3,700 (consisting of $5,000 for commercial enrollees and $1,500 for Medi-Cal enrollees). With bill enactment, changes in payer mix will increase the average cost to $4,100.
- Impacts on premiums. To cover the new scalp cooling benefit, CHBRP estimates that total annual premiums paid by employers and enrollees would increase by approximately $4,010,000—an increase of 0.0023%, or between $0.005 and $0.029 per member per month (PMPM). Employer premiums are expected to increase by $2,672,000 (between $0.0104 and $0.0235 PMPM), enrollee premiums in the large- and small-group markets are expected to increase by $647,000 (about $0.005 PMPM), and premiums in the individual market are expected to increase by $511,000 ($0.005 PMPM in CDI-regulated plans and $0.0173 PMPM in DMHC-regulated plans). Medi-Cal Managed Care expenses are expected to increase by $180,000 ($0.0019 PMPM).
- Impacts on benefit users. CHBRP projects an increase in utilization including both new users and those who did not previously purchase a noncovered service, increasing total enrollee cost-sharing by $305,000. For users who did not have baseline coverage, projected expenses are projected to decrease by $934,000. Average annual enrollee out-of-pocket expenses depend on the user and their insurance type. While users with scalp cooling coverage would experience no change in their expenses, a user without baseline coverage would experience significant average annual savings, ranging from $0 for Medi-Cal enrollees, to $4,000 in the individual market and $4,810 in the CalPERS market. Because new users of the scalp-cooling benefit will be subject to cost-sharing, their average annual expenses are expected to increase by a range of $180 in CalPERS to $1,010 in the individual market (excluding Medi-Cal, which is not subject to cost-sharing).
- Essential health benefits (EHBs). Due to amendments adopted in Senate Appropriations, this bill does not impact EHBs.
- Public health. Based on a literature-based rate of meaningful hair preservation of about 49%, CHBRP estimates that this bill would result in 333 of the newly-covered 680 enrollees experiencing significantly less hair loss than they otherwise would. Although 680 users is too small a number to impact public health outcomes at the population level, the individual-level benefit of scalp cooling may be clinically meaningful. According to CHBRP, although randomized control trials of scalp cooling have not found significant improvements in quality-of-life measures, chemotherapy-induced alopecia is consistently associated with psychological distress, anxiety, and reduced wellbeing in the broader literature. Beyond patient discomfort that could lead to the discontinuation of the treatment, scalp cooling is not associated with patient harm. Studies have shown no difference in rates of scalp metastasis between patients who used scalp cooling and those who did not.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee, there are unknown, likely minor costs for DMHC and CDI for state administration, and unknown ongoing General Fund costs, potentially tens of thousands, due to increased CalPERS plan premiums.
SUPPORT: (Verified 8/21/26)
Association of Northern California Oncologists
Biocom California
California Medical Association
CenCal Health
Cooler Heads Care, Inc.
Cottage Health
Health Access California
Medical Oncology Association of Southern California
Oncology Nursing Society
Paxman US, Inc.
The Rapunzel Project
Five individuals
OPPOSITION: (Verified 8/21/26)
America's Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: Groups like the California Medical Association, Cottage Health, and the Oncology Nursing Society share that this bill is an important step toward improving supportive care for cancer patients. For many patients, hair loss represents a loss of privacy, identity, and control during a particularly vulnerable period, particularly for working adults and parents whose personal and professional lives may be significantly affected by chemotherapy-induced hair loss. Paxman and Cooler Heads Care share that even though supportive remedies are available for nearly every major chemotherapy side effect, scalp cooling is mostly a cash-pay service, and they support this bill’s efforts to align insurance coverage with established clinical practice, professional guidelines, and existing treatment infrastructure. Health Access states that although Medicare expanded coverage for scalp cooling systems in January, they are not yet a Medi-Cal benefit and inconsistently covered by private insurance, often leaving patients to pay out-of-pocket costs ranging from $3,000 to $6,000. Health Access appreciates that this bill provides the same supportive care to low-income Californians despite their income status, a sentiment echoed by CenCal Health, the local Medi-Cal managed care plan in Santa Barbara and San Luis Obispo counties. Biocom specifically supports the bill’s use of the FDA regulatory framework as its coverage standard. The Rapunzel Project requests an amendment to reimburse scalp cooling regardless of the method by which scalp cooling is delivered. They claim that including manual cold caps is essential for equitable access, as automatic scalp cooling devices are less common in smaller community practices and rural areas. They provide language from New York, Louisiana, West Virginia, Maryland, and Connecticut legislation that defines scalp cooling systems in a technology-neutral way.
ARGUMENTS IN OPPOSITION: A coalition letter from the Association of Life and Health Insurance Companies, the California Association of Health Plans, and America’s Health Insurance Plans state that this bill is one of eleven health insurance mandate bills that they oppose this session on the principle that the bills will increase health insurance premiums, harming health care affordability, access, and flexibility for small businesses and individuals. They share that the Office of Health Care Affordability (OHCA) has established statewide health care spending growth target of 3%, which is being phased in at 3.5% for 2025 and 2026, 3.2% in 2027 and 2028, and 3% percent in 2029 and beyond. These associations emphasize that while OHCA is working to curb healthcare costs and ensure resources are allocated efficiently, adding new mandates could disrupt these efforts by driving up costs for insurers, employers, and consumers, making it difficult for health care entities to meet the established targets. They claim that at this moment, the state should focus on healthcare stability and affordability for all Californians.
ASSEMBLY FLOOR: 67-1, 5/27/26
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Davies, Elhawary, Fong, Gabriel, Garcia, Gipson, Jeff Gonzalez, Mark González, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Johnson, Kalra, Krell, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Michelle Rodriguez, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
NOES: DeMaio
NO VOTE RECORDED: Castillo, Chen, Dixon, Ellis, Flora, Gallagher, Hadwick, Lackey, Celeste Rodriguez, Sanchez, Ta, Tangipa
Prepared by: Natalie Gehred / HEALTH / (916) 651-4111
8/24/26 10:54:07
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | AB 1682 |
THIRD READING
Bill No: AB 1682
Author: Hart (D), et al.
Amended: 8/13/26 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 11-0, 6/24/26
AYES: Weber Pierson, Valladares, Caballero, Durazo, Gonzalez, Grove, Menjivar, Padilla, Pérez, Rubio, Smallwood-Cuevas
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/13/26
AYES: Cervantes, Seyarto, Cabaldon, Dahle, Grayson, Richardson, Wahab
ASSEMBLY FLOOR: 67-1, 5/27/26 - See last page for vote
SUBJECT: Health care coverage: scalp cooling
SOURCE: Author
DIGEST:
This bill (1) requires large group health care service plan contracts or health insurance policies to provide coverage, and small group health care service plan contracts or health insurance policies to offer coverage, for scalp cooling as prescribed by a health care provider in connection with chemotherapy in which alopecia-inducing chemotherapeutic agents are used; (2) expands the Medi-Cal schedule of benefits to include scalp cooling, subject to utilization controls and medical necessity.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975; California Department of Insurance (CDI) to regulate health and other insurance; and the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [Health & Safety Code (HSC) §1340, et seq., Insurance Code (INS) §106, et seq., and Welfare & Institutions Code (WIC) §14000, et seq.]
- Requires an individual and small group health plan contracts and insurance policies to include at a minimum coverage for Essential Health Benefits (EHBs) pursuant to the Affordable Care Act (ACA), and as outlined below:
- Health benefits within the ten federally required categories identified in the ACA;
- Health benefits covered by the Kaiser Foundation Health Plan Small Group HMO 30 (Kaiser Small Group HMO), as this plan was offered during the first quarter of 2014, regardless of whether the benefits are specifically referenced in the evidence of coverage or in the contract or policy;
- Medically necessary basic health care services, as specified;
- Health benefits mandated to be covered pursuant to statutes enacted before December 31, 2011, as described; and,
- Health benefits covered by the plan or policy that are not otherwise required to be covered, as specified. [HSC §1367.005 and INS §10112.27]
- Defines “basic health care services” as physician services including consultation and referral, hospital inpatient services and ambulatory care services, diagnostic laboratory and therapeutic radiologic services, home health services, preventative health services, emergency health care services, including ambulance and ambulance transport services and out-of-area coverage (including those provided through the 911 emergency response system), and hospice care. [HSC §1345]
- Requires health plan contracts and insurance policies, except specialized plans and policies, to provide coverage for screening for, diagnosis of, and treatment for, breast cancer. [HSC §1367.6 and INS §10123.8]
This bill:
- Requires large group health plan contracts and insurance policies to cover scalp cooling as prescribed by a health care provider in connection with chemotherapy with alopecia-inducing chemotherapeutic agents.
- Requires small group health plan contracts and insurance policies to offer coverage for scalp cooling as prescribed by a health care provider in connection with chemotherapy with alopecia-inducing chemotherapeutic agents.
- Requires Medi-Cal benefits to include scalp cooling as prescribed by a health care provider in connection with chemotherapy with alopecia-inducing chemotherapeutic agents, subject to utilization controls and medical necessity.
- Defines “scalp cooling” as the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Clarifies that “scalp cooling” does not include non-FDA-cleared scalp cooling products.
Comments
According to the author of this bill:
“This bill is a critical step toward improving supportive cancer care and ensuring that patients receiving chemotherapy can have access to medically necessary treatment. Scalp cooling is an FDA-cleared, evidence-based therapy for chemotherapy-induced hair loss, but insurance coverage remains inconsistent and unpredictable. This leaves many patients to pay significant out-of-pocket costs during an already difficult time. By requiring California health plans and health insurers to cover scalp cooling when prescribed by a provider, this bill helps remove a major financial barrier and supports patients’ mental health.”
Background
Chemotherapy-induced alopecia. According to a 2020 review in Current Oncology, chemotherapy-induced alopecia is the hair loss that occurs when the cytotoxic drugs in chemotherapy regimens kill rapidly proliferating cells, which, beyond cancerous cells, includes growing hair follicle cells. Because up to 90% of scalp hair follicles are in the growth phase at any given time, scalp hair loss within the first several weeks of chemotherapy initiation can be significant. According to the American Cancer Society, the likelihood of hair loss is dependent on the chemotherapy regimen prescribed. Chemotherapy-induced alopecia is generally reversible three to six months after cessation of chemotherapy, although the new hair may show different texture and color, and some patients experience no hair regrowth or only partial hair regrowth. The Current Oncology review highlights that chemotherapy-related hair loss has been shown to have a negative impact on patients’ self-esteem, body image, sexuality, and overall quality of life.
Scalp cooling. According to the American Cancer Society, scalp cooling works to prevent hair loss by restricting the blood flow to the scalp, which decreases the amount of chemotherapy drug that gets to the hair follicles. Scalp cooling is used before, during, and after each chemotherapy session. Scalp cooling is an established practice in oncology care; in 2022, the American Medical Association adopted a resolution supporting insurance coverage for scalp cooling and recently updated its billing codes for scalp cooling to Category 1, or permanent codes that reflect accepted procedures or services.
Scalp cooling can be performed with either manual cold caps or automated scalp cooling systems. According to the American Cancer Society, manual cold caps are manually cooled in a freezer or with dry ice and must be switched every 30 minutes to manually regulate the temperature and prevent the cap from warming. In contrast, automated scalp cooling devices automatically circulate a liquid or gel around a snug-fitting silicone cap to cool the scalp to a specific temperature. Three automated scalp cooling systems are available for patients: DigniCap, Paxman, and Amma. Medicare currently covers automated scalp cooling when performed with FDA-approved, automated scalp cooling systems, not manual cold caps. One 2024 meta-analysis examining the efficacy of automatic scalp-cooling devices and manual cooling products showed no significant differences in hair preservation on various chemotherapy regimens.
California Health Benefit Review Program (CHBRP) analysis. Key findings include:
- Coverage impacts and enrollees covered. This bill applies to all state-regulated health insurance. CHBRP estimates that 22.8 million Californians (60% of the state) have Medi-Cal or CDI- and DMHC-regulated insurance subject to this bill. Approximately 47% of Californians have plans already compliant with this bill. This bill would extend a scalp cooling benefit to the remaining 12 million enrollees.
- Medical effectiveness. There is strong evidence that FDA-cleared automated scalp cooling devices are effective in reducing chemotherapy-induced alopecia. Some evidence suggests that scalp cooling may be less effective for patients with different hair types, such as for Black patients with curly hair. There is strong evidence that scalp cooling does not raise the risk of scalp metastasis.
- Utilization. CHBRP estimates that 630 enrollees use scalp cooling to prevent chemotherapy-induced hair loss, 440 of which have coverage at baseline and 190 of which do not. This bill would result in 680 additional enrollees receiving scalp cooling therapy, 90 of which had coverage at baseline and would continue to have coverage, but with increased utilization due to an increase in availability and awareness. The remaining 590 additional enrollees are those who did not have coverage but would have coverage with the enactment of this bill.
- Medi-Cal. This bill includes Medi-Cal enrollees. Because Medi-Cal coverage generally does not include enrollee cost-sharing, those with Medi-Cal will not experience any change in the cost of utilizing the scalp cooling benefit.
- Impact on expenditures. CHBRP estimates that the average cost of scalp cooling per enrollee for a course of chemotherapy over a year is $3,700 (consisting of $5,000 for commercial enrollees and $1,500 for Medi-Cal enrollees). With bill enactment, changes in payer mix will increase the average cost to $4,100.
- Impacts on premiums. To cover the new scalp cooling benefit, CHBRP estimates that total annual premiums paid by employers and enrollees would increase by approximately $4,010,000—an increase of 0.0023%, or between $0.005 and $0.029 per member per month (PMPM). Employer premiums are expected to increase by $2,672,000 (between $0.0104 and $0.0235 PMPM), enrollee premiums in the large- and small-group markets are expected to increase by $647,000 (about $0.005 PMPM), and premiums in the individual market are expected to increase by $511,000 ($0.005 PMPM in CDI-regulated plans and $0.0173 PMPM in DMHC-regulated plans). Medi-Cal Managed Care expenses are expected to increase by $180,000 ($0.0019 PMPM).
- Impacts on benefit users. CHBRP projects an increase in utilization including both new users and those who did not previously purchase a noncovered service, increasing total enrollee cost-sharing by $305,000. For users who did not have baseline coverage, projected expenses are projected to decrease by $934,000. Average annual enrollee out-of-pocket expenses depend on the user and their insurance type. While users with scalp cooling coverage would experience no change in their expenses, a user without baseline coverage would experience significant average annual savings, ranging from $0 for Medi-Cal enrollees, to $4,000 in the individual market and $4,810 in the CalPERS market. Because new users of the scalp-cooling benefit will be subject to cost-sharing, their average annual expenses are expected to increase by a range of $180 in CalPERS to $1,010 in the individual market (excluding Medi-Cal, which is not subject to cost-sharing).
- Essential health benefits (EHBs). Due to amendments adopted in Senate Appropriations, this bill is not expected to exceed EHBs.
- Public health. Based on a literature-based rate of meaningful hair preservation of about 49%, CHBRP estimates that this bill would result in 333 of the newly-covered 680 enrollees experiencing significantly less hair loss than they otherwise would. Although 680 users is too small a number to impact public health outcomes at the population level, the individual-level benefit of scalp cooling may be clinically meaningful. According to CHBRP, although randomized control trials of scalp cooling have not found significant improvements in quality-of-life measures, chemotherapy-induced alopecia is consistently associated with psychological distress, anxiety, and reduced wellbeing in the broader literature. Beyond patient discomfort that could lead to the discontinuation of the treatment, scalp cooling is not associated with patient harm. Studies have shown no difference in rates of scalp metastasis between patients who used scalp cooling and those who did not.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee, there are unknown, likely minor costs for DMHC and CDI for state administration, and unknown ongoing General Fund costs, potentially tens of thousands, due to increased CalPERS plan premiums.
Association of Northern California Oncologists
Biocom California
California Medical Association
CenCal Health
Cooler Heads Care, Inc.
Cottage Health
Health Access California
Medical Oncology Association of Southern California
Oncology Nursing Society
Paxman US, Inc.
The Rapunzel Project
Two individuals
OPPOSITION: (Verified 8/14/26)
America's Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: Groups like the California Medical Association, Cottage Health, and the Oncology Nursing Society share that this bill is an important step toward improving supportive care for cancer patients. For many patients, hair loss represents a loss of privacy, identity, and control during a particularly vulnerable period, particularly for working adults and parents whose personal and professional lives may be significantly affected by chemotherapy-induced hair loss. Paxman and Cooler Heads Care share that even though supportive remedies are available for nearly every major chemotherapy side effect, scalp cooling is mostly a cash-pay service, and they support this bill’s efforts to align insurance coverage with established clinical practice, professional guidelines, and existing treatment infrastructure. Health Access states that although Medicare expanded coverage for scalp cooling systems in January, they are not yet a Medi-Cal benefit and inconsistently covered by private insurance, often leaving patients to pay out-of-pocket costs ranging from $3,000 to $6,000. Health Access appreciates that this bill provides the same supportive care to low-income Californians despite their income status, a sentiment echoed by CenCal Health, the local Medi-Cal managed care plan in Santa Barbara and San Luis Obispo counties. Biocom specifically supports the bill’s use of the FDA regulatory framework as its coverage standard. The Rapunzel Project requests an amendment to reimburse scalp cooling regardless of the method by which scalp cooling is delivered. They claim that including manual cold caps is essential for equitable access, as automatic scalp cooling devices are less common in smaller community practices and rural areas. They provide language from New York, Louisiana, West Virginia, Maryland, and Connecticut legislation that defines scalp cooling systems in a technology-neutral way.
ARGUMENTS IN OPPOSITION: A coalition letter from the Association of Life and Health Insurance Companies, the California Association of Health Plans, and America’s Health Insurance Plans state that this bill is one of eleven health insurance mandate bills that they oppose this session on the principle that the bills will increase health insurance premiums, harming health care affordability, access, and flexibility for small businesses and individuals. They share that the Office of Health Care Affordability (OHCA) has established statewide health care spending growth target of 3%, which is being phased in at 3.5% for 2025 and 2026, 3.2% in 2027 and 2028, and 3% percent in 2029 and beyond. These associations emphasize that while OHCA is working to curb healthcare costs and ensure resources are allocated efficiently, adding new mandates could disrupt these efforts by driving up costs for insurers, employers, and consumers, making it difficult for health care entities to meet the established targets. They claim that at this moment, the state should focus on healthcare stability and affordability for all Californians.
ASSEMBLY FLOOR: 67-1, 5/27/26
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Davies, Elhawary, Fong, Gabriel, Garcia, Gipson, Jeff Gonzalez, Mark González, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Johnson, Kalra, Krell, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Michelle Rodriguez, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
NOES: DeMaio
NO VOTE RECORDED: Castillo, Chen, Dixon, Ellis, Flora, Gallagher, Hadwick, Lackey, Celeste Rodriguez, Sanchez, Ta, Tangipa
Prepared by: Natalie Gehred / HEALTH / (916) 651-4111
8/17/26 10:38:09
**** END ****
SENATE COMMITTEE ON
Senator Sabrina Cervantes, Chair
2025 - 2026 Regular Session
AB 1682 (Hart) - Health care coverage: scalp cooling
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
AB 1682 would require health plans and insurers, and the Medi-Cal program, to provide coverage for scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer.
*********** ANALYSIS ADDENDUM – SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on August 13, 2026
Fiscal Impact:
- Unknown costs, likely minor, for the Department of Managed Health Care and the California Department of Insurance for state administration.
- Unknown ongoing General Fund costs, potentially tens of thousands, due to increased CalPERS plan premiums.
Author Amendments:
Require small group plans and insurers to offer, rather than provide, scalp cooling; clarify the definition of scalp cooling; and clarify the Medi-Cal program requirements.
-- END --
SENATE COMMITTEE ON
Senator Sabrina Cervantes, Chair
2025 - 2026 Regular Session
AB 1682 (Hart) - Health care coverage: scalp cooling
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
AB 1682 would require health plans and insurers, and the Medi-Cal program, to provide coverage for scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer.
Fiscal Impact:
- The Department of Health Care Services (DHCS) indicates there may be increased utilization of scalp cooling services for Medi-Cal members with cancer in instances where it may not be medically necessary due to the absence of clinically appropriate utilization management controls. This could result in increased Medi-Cal program costs of approximately $500,000 ($250,000 General Fund and $250,000 federal funds) for each five percent increase in utilization.
- The Department of Managed Health Care anticipates minor and absorbable costs for state administration.
- The California Department of Insurance (CDI) estimates costs of $6,000 in 2026-27 and $18,000 in 2027-28 for state administration (Insurance Fund).
- Unknown ongoing General Fund costs, potentially tens of thousands, due to increased CalPERS plan premiums.
Background:
According to the California Health Benefits Review Program (CHBRP), chemotherapy-induced alopecia is typically temporary and hair usually begins to regrow within weeks to months after treatment ends. Chemotherapy-induced alopecia typically begins 2 to 4 weeks after the start of treatment and is consistently among the most commonly reported and distressing side effects of cancer treatment. Scalp cooling works by cooling the scalp before, during, and after chemotherapy infusion to reduce the amount of drug delivered to hair follicles, thereby aiming to reduce hair loss. The U.S. Food and Drug Administration (FDA)-cleared scalp cooling systems are automated, which allows cool fluid to circulate through the cap to maintain the desired temperature for long periods of time. Manual cold caps, by contrast, are stored in freezers or with dry ice and must be swapped out by hand throughout the infusion as they warm up.
Proposed Law:
Specific provisions of the bill would:
- Define “scalp cooling’’ as the use of a medical device or system cleared by the FDA applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss); and specify that “scalp cooling” does not include non-FDA-cleared cold caps or any non-FDA-cleared scalp cooling products, regardless of whether those products are described as “cold cap therapy” or similar terminology.
- Require health plans and insurers to provide coverage for scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer; and provide that coverage may be subject to copayments, coinsurance, or deductibles, provided that the copayments, coinsurance, or deductibles applicable to scalp cooling are no less favorable to an enrollee/insured than the copayments, coinsurance, or deductibles that apply to coverage for oncology supportive care services under the same contract/policy.
- Require that scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer, is a covered benefit under the Medi-Cal program; and provide that coverage may be subject to copayments or deductibles, provided that the copayments or deductibles applicable to scalp cooling are no less favorable to a beneficiary than the copayments or deductibles that apply to oncology supportive care services that are covered benefits under the Medi-Cal program.
Staff Comments:
The CHBRP analysis of AB 1682 (introduced version) estimates the bill would increase total plan premiums for newly covered benefits by approximately $4,010,000 for DMHC-regulated plans and CDI-regulated policies. This includes an increase of $217,000 for CalPERS plans and $180,000 for Medi-Cal plans.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Akilah Weber Pierson, Chair
BILL NO: AB 1682
AUTHOR: | Hart | ||
VERSION: | February 2, 2026 | ||
HEARING DATE: | June 24, 2026 | ||
CONSULTANT: | Natalie Gehred | ||
SUBJECT: Health care coverage: scalp cooling.
SUMMARY:
Requires health plans, health insurers, and Medi-Cal to provide coverage for scalp cooling as prescribed by a health care provider in connection with chemotherapy. Requires cost-sharing for scalp cooling to be no less favorable to the patient than cost-sharing applied to oncology supportive care services.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975; California Department of Insurance (CDI) to regulate health and other insurance; and the Department of Health Care Services to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Requires an individual or small group health plan contract or insurance policy to include at a minimum coverage for Essential Health Benefits (EHBs) pursuant to the Affordable Care Act (ACA), and as outlined below:
- Health benefits within the ten federally required categories identified in the ACA;
- Health benefits covered by the Kaiser Foundation Health Plan Small Group HMO 30 (Kaiser Small Group HMO), as this plan was offered during the first quarter of 2014, regardless of whether the benefits are specifically referenced in the evidence of coverage or plan contract for that plan;
- Medically necessary basic health care services, as specified;
- Health benefits mandated to be covered by the plan pursuant to statutes enacted before December 31, 2011, as described; and,
- Health benefits covered by the plan that are not otherwise required to be covered, as specified. [HSC §1367.005 and INS §10112.27]
- Defines “basic health care services” as physician services including consultation and referral, hospital inpatient services and ambulatory care services, diagnostic laboratory and therapeutic radiologic services, home health services, preventative health services, emergency health care services, including ambulance and ambulance transport services and out-of-area coverage (including those provided through the 911 emergency response system), and hospice care. [HSC §1345]
- Requires health plan contracts and insurance policies, except specialized plans and policies, to provide coverage for screening for, diagnosis of, and treatment for, breast cancer. [HSC §1367.6 and INS §10123.8]
This bill:
- Requires health plans, health insurers, and Medi-Cal to provide coverage for scalp cooling, as prescribed by a health care provider in connection with chemotherapy for people with cancer.
- Allows coverage to be subject to copayments, coinsurance, or deductibles, provided that the cost-sharing is no less favorable to a patient than the cost-sharing applied to oncology supportive care services.
- Defines “scalp cooling” as the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss). Clarifies that “scalp cooling” does not include non-FDA-cleared scalp cooling products.
FISCAL EFFECT:
According to the Assembly Committee on Appropriations, the California Health Benefits Review Program (CHBRP) estimates costs to the Medi-Cal program would increase by $180,000 (General Fund (GF)), federal funds). CHBRP estimates this bill will increase employer premiums for health plans regulated by DMHC in CalPERS by $217,000, of which some costs would be paid by enrollees and non-state employers. There would be additional state costs for the 26% of CalPERS members with health insurance policies regulated by CDI. The state's share of CalPERS costs would likely be around $150,000 (GF). CDI estimates costs of $6,000 in fiscal year (FY) 2026-27 and $18,000 in FY 2027-28 to review insurance policy forms (Insurance Fund). DMHC anticipates minor and absorbable costs. CHBRP estimates this bill will increase overall premiums paid by employers and enrollees by $4 million annually.
PRIOR VOTES:
Assembly Floor: | 67 - 1 |
Assembly Appropriations Committee: | 12 - 0 |
Assembly Health Committee: | 14 - 0 |
COMMENTS:
- Author’s statement. According to the author, this bill is a critical step toward improving supportive cancer care and ensuring that patients receiving chemotherapy can have access to medically necessary treatment. Scalp cooling is an FDA-cleared, evidence-based therapy for chemotherapy-induced hair loss, but insurance coverage remains inconsistent and unpredictable. This leaves many patients to pay significant out-of-pocket costs during an already difficult time. By requiring California health plans and health insurers to cover scalp cooling when prescribed by a provider, this bill helps remove a major financial barrier and supports patients’ mental health.
- Chemotherapy-induced alopecia. According to a 2020 review in Current Oncology, chemotherapy-induced alopecia is the hair loss that occurs when the cytotoxic drugs in chemotherapy regimens kill rapidly proliferating cells, which, beyond cancerous cells, includes growing hair follicle cells. Because up to 90% of scalp hair follicles are in the growth phase at any given time, scalp hair loss within the first several weeks of chemotherapy initiation can be significant. According to the American Cancer Society, the likelihood of hair loss is dependent on the chemotherapy regimen prescribed. Chemotherapy-induced alopecia is generally reversible three to six months after cessation of chemotherapy, although the new hair may show different texture and color, and some patients experience no hair regrowth or only partial hair regrowth. The Current Oncology review highlights that chemotherapy-related hair loss has been shown to have a negative impact on patients’ self-esteem, body image, sexuality, and overall quality of life; in a study of 179 male and female patients who developed alopecia, 56.4% of patients felt that it was the worst side effect of chemotherapy, and 72% patients said hair loss was affecting their social life. According to an integrative review on the effects of alopecia among women receiving chemotherapy published in the European Journal of Oncology Nursing in 2020, despite preparation for potential alopecia, women still experience shock and trauma when alopecia occurs. The review also identified a struggle with the complexities of a visual cancer identity, and reported a considerable impact on women’s social relationships.
- Scalp cooling. According to the American Cancer Society, scalp cooling works to prevent hair loss by restricting the blood flow to the scalp, which decreases the amount of chemotherapy drug that gets to the hair follicles. Scalp cooling is used before, during, and after each chemotherapy session. Scalp cooling is an established practice in oncology care; in 2022, the American Medical Association adopted a resolution supporting insurance coverage for scalp cooling and recently updated its billing codes for scalp cooling to Category 1, or permanent codes that reflect accepted procedures or services. The National Comprehensive Cancer Network also recommends scalp cooling as a treatment option for those receiving chemotherapy for breast and ovarian cancer, although with the caveat that results may be less effective with treatment regimens containing anthracycline.
Scalp cooling can be performed with either manual cold caps or automated scalp cooling systems. According to the American Cancer Society, manual cold caps are manually cooled in a freezer or with dry ice and must be switched every 30 minutes to manually regulate the temperature and prevent the cap from warming. In contrast, automated scalp cooling devices automatically circulate a liquid or gel around a snug-fitting silicone cap to cool the scalp to a specific temperature. Automated caps, although they do not require patients to privately rent caps or bring along an aide to help switch caps, are only available at select infusion centers, concentrated in large urban cancer centers and academic medical institutions, according to CHBRP. Three automated scalp cooling systems are available for patients: DigniCap, Paxman, and Amma. Medicare currently covers automated scalp cooling when performed with FDA-approved, automated scalp cooling systems, not manual cold caps. One 2024 meta-analysis examining the efficacy of automatic scalp-cooling devices and manual cooling products showed no significant differences in hair preservation on various chemotherapy regimens.
- CHBRP analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Key findings include:
- Coverage impacts and enrollees covered. This bill applies to all state-regulated health insurance. CHBRP estimates that 22.8 million Californians (60% of the state) have Medi-Cal or CDI- and DMHC-regulated insurance subject to this bill. At baseline, 47% of Californians have plans already compliant with this bill. This bill would extend a scalp cooling benefit to the remaining 12 million enrollees.
- Medical effectiveness. There is strong evidence that FDA-cleared automated scalp cooling devices are effective in reducing chemotherapy-induced alopecia. Some evidence suggests that scalp cooling may be less effective for patients with different hair types, such as for Black patients with curly hair. There is strong evidence that scalp cooling does not raise the risk of scalp metastasis.
- Utilization. CHBRP estimated that at baseline, 630 enrollees use scalp cooling to prevent chemotherapy-induced hair loss, 440 of which have coverage at baseline and 190 of which do not. This bill would result in 680 additional enrollees receiving scalp cooling therapy, 90 of which had coverage at baseline and would continue to have coverage postmandate, but with increased utilization due to an increase in availability and awareness. The remaining 590 additional enrollees are those who did not have coverage at baseline but would have coverage postmandate.
- Medi-Cal. This bill includes Medi-Cal enrollees. Because Medi-Cal coverage generally does not include enrollee cost-sharing, those with Medi-Cal will not experience any change in the cost of utilizing the scalp cooling benefit post-mandate.
- Impact on expenditures. CHBRP estimates that the average cost of scalp cooling per enrollee for a course of chemotherapy over a year is $3,700 (consisting of $5,000 for commercial enrollees and $1,500 for Medi-Cal enrollees). Postmandate, changes in payer mix will increase the average cost to $4,100.
- Impacts on premiums. To cover the new scalp cooling benefit, CHBRP estimates that total annual premiums paid by employers and enrollees would increase by approximately $4,010,000—an increase of 0.0023%, or between $0.005 and $0.029 per member per month (PMPM). Employer premiums are expected to increase by $2,672,000 (between $0.0104 and $0.0235 PMPM), enrollee premiums in the large- and small-group markets are expected to increase by $647,000 (about $0.005 PMPM), and premiums in the individual market are expected to increase by $511,000 ($0.005 PMPM in CDI-regulated plans and $0.0173 PMPM in DMHC-regulated plans). Medi-Cal Managed Care expenses are expected to increase by $180,000 ($0.0019 PMPM).
- Impacts on benefit users. CHBRP projects an increase in utilization postmandate, including both new users and those who did not previously purchase a noncovered service, increasing total enrollee cost-sharing by $305,000 postmandate. For users who did not have baseline coverage, postmandate projected expenses are projected to decrease by $934,000. Average annual enrollee out-of-pocket expenses depend on the user and their insurance type. While users with baseline scalp cooling coverage would experience no change in their expenses, a user without baseline coverage would experience significant average annual savings postmandate, ranging from $0 for Medi-Cal enrollees, to $4,000 in the individual market and $4,810 in the CalPERS market. Because new users of the scalp-cooling benefit will be subject to cost-sharing, their average annual expenses are expected to increase by a range of $180 in CalPERS to $1,010 in the individual market (excluding Medi-Cal, which is not subject to cost-sharing).
- EHBs. It is unclear if scalp cooling under this bill would exceed EHBs. CHBRP’s survey to carriers found that many carriers already cover scalp cooling. If scalp cooling is considered part of existing coverage, or if similar coverage determinations are made for scalp cooling as other benefit coverage mandates, then scalp cooling would not exceed EHBs. If scalp cooling is considered a new and additional benefit for coverage, then this bill may exceed EHBs, costing the state $1,442,000 in defrayal costs in 2027.
- Public health. Based on a literature-based rate of meaningful hair preservation of about 49%, CHBRP estimates that this bill would result in 333 of the newly-covered 680 enrollees experiencing significantly less hair loss than they otherwise would. Although 680 users is too small a number to impact public health outcomes at the population level, the individual-level benefit of scalp cooling may be clinically meaningful. According to CHBRP, although randomized control trials of scalp cooling have not found significant improvements in quality-of-life measures, chemotherapy-induced alopecia is consistently associated with psychological distress, anxiety, and reduced wellbeing in the broader literature. Therefore, whether experiencing less hair loss translates to measurable improvements in quality of life or reductions in mental health service use is uncertain, it may reduce distress, anxiety, and self-image impacts on an individual basis. Beyond patient discomfort that could lead to the discontinuation of the treatment (a 2025 metareview in Breast Cancer Research and Treatment found a discontinuation rate of about 18%), scalp cooling is not associated with patient harm. Studies have shown no difference in rates of scalp metastasis between patients who used scalp cooling and those who did not.
- Impacts on disparities. This bill could reduce income-related barriers to accessing scalp cooling but is not anticipated to reduce other disparities in access like the lack of scalp cooling devices in certain areas, the time burden of lengthier chemotherapy sessions, or potential fit issues for patients with tightly coiled hair. CHBRP states that the impact on racial or ethnic disparities in utilization is unknown, and the evidence on whether scalp cooling is equally effective across hair types is limited and mixed.
- FDA clearance process. According to the FDA, the regulation of medical devices is risk-based, which means that the level of regulatory control necessary to demonstrate a reasonable assurance of safety and effectiveness is matched to the level of risk of the device. Automated scalp cooling devices are considered class II medical devices, meaning that they are classified as moderate-risk devices, and are cleared under Section 510(k) of the Food, Drug, and Cosmetic Act, which requires registered device manufacturers to notify FDA of their intent to market a medical device at least 90 days in advance. The review standard for the 510(k) process is comparative, meaning that the manufacturer must provide scientific, non-clinical, and clinical data, as appropriate, to determine if a new device is substantially equivalent to a device that is already on the market. Unlike automated scalp cooling devices, manual cold cap products are not regulated by the FDA. While Medicare coverage of scalp-cooling devices requires FDA clearance, some state laws—like those in New York and Louisiana—do not.
- Prior legislation. AB 2668 (Berman of 2024) would have required health plan, insurer, and Medi-Cal coverage of cranial prosthesis for individuals experiencing permanent or temporary medical hair loss. AB 2668 also would have limited coverage to $750. AB 2668 was held on the Assembly Appropriations suspense file.
AB 2464 (Dutra of 2002) would have required a health plan or insurer that provides medical and surgical benefits with respect to the treatment of cancer treated by chemotherapy or radiation therapy to provide coverage for a wig or hairpiece necessary for the comfort and dignity of the enrollee. AB 2464 was not heard in the Assembly Health Committee.
- Support. Groups like the California Medical Association, Cottage Health, and the Oncology Nursing Society share that this bill is an important step toward improving supportive care for cancer patients, as hair loss is not simply a cosmetic issue. For many patients, it represents a loss of privacy, identity, and control during a particularly vulnerable period, particularly for working adults and parents whose personal and professional lives may be significantly affected by chemotherapy-induced hair loss. Paxman and Cooler Heads Care share that even though supportive remedies are available for nearly every major chemotherapy side effect, scalp cooling is mostly a cash-pay service. Paxman states that the average patient out-of-pocket cost for scalp cooling is approximately $2,500 per course of treatment, posing a significant financial barrier, especially when cancer patients are also managing the cost of chemotherapy. They support this bill’s efforts to align insurance coverage with established clinical practice, professional guidelines, and existing treatment infrastructure. Health Access states that although Medicare expanded coverage for scalp cooling systems in January, they are not yet covered by Medi-Cal and inconsistently covered by private insurance, often leaving patients to pay out-of-pocket costs ranging from $3,000 to $6,000. Health Access appreciates that this bill provides the same supportive care to low-income Californians despite their income status. CenCal Health, the local Medi-Cal managed care plan in Santa Barbara and San Luis Obispo counties, state that they currently cover scalp cooling under the Treatment Authorization Request process. However, this process requires additional administrative steps that can delay care for members, so CenCal Health supports establishing scalp cooling as a Medi-Cal benefit. Lastly, Biocom specifically supports the bill’s use of the FDA regulatory framework as its coverage standard. They state that by limiting the coverage mandate to FDA-cleared devices, the bill ensures that patients receive access to technologies that have met rigorous standards for safety and effectiveness, protecting both patients and the integrity of the coverage benefit. The Rapunzel Project supports efforts to expand access to scalp cooling for patients undergoing chemotherapy, but also request an amendment to reimburse scalp cooling, not prescribe the method by which scalp cooling is delivered. They claim that including manual cold caps is essential for equitable access, as automatic scalp cooling devices are less common in smaller community practices and rural areas. Finally, they provide language from New York, Louisiana, West Virginia, Maryland, and Connecticut legislation that defines scalp cooling systems in a technology-neutral way.
- Opposition. A coalition letter from the Association of Life and Health Insurance Companies, the California Association of Health Plans, and America’s Health Insurance Plans state that this bill is one of eleven health insurance mandate bills that they oppose this session on the principle that the bills will increase health insurance premiums, harming health care affordability, access, and flexibility for small businesses and individuals. They share that the Office of Health Care Affordability (OHCA) has established statewide health care spending growth target of 3%, which is being phased in at 3.5% for 2025 and 2026, 3.2% in 2027 and 2028, and 3% percent in 2029 and beyond. These associations emphasize that while OHCA is working to curb healthcare costs and ensure resources are allocated efficiently, adding new mandates could disrupt these efforts by driving up costs for insurers, employers, and consumers, making it difficult for health care entities to meet the established targets. They claim that at this moment, the state should focus on healthcare stability and affordability for all Californians.
- Policy comment. This bill has the potential to exceed EHBs, which means the state will have to pay for the incremental costs to offset federal subsidies for people with qualifying insurance. CHBRP estimates that if scalp cooling is determined to exceed EHBs by DMHC and CDI, this bill would require the state to pay about $1,442,000 in defrayal costs in 2027.
SUPPORT AND OPPOSITION:
Support: Association of Northern California Oncologists
Biocom California
California Medical Association
CenCal Health
Cooler Heads Care, Inc.
Cottage Health
Health Access California
Medical Oncology Association of Southern California
Oncology Nursing Society
Paxman US, Inc.
The Rapunzel Project
Two individuals
Oppose: America's Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1682
Author:(Hart)
As Introduced Ver:February 2, 2026
Majority vote
SUMMARY
Requires a health plan, health insurer, and the Medi-Cal program, to provide coverage for scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer. Requires cost-sharing for scalp cooling to be no less favorable to an enrollee than cost-sharing for oncology supportive care services. Defines "scalp cooling" as the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss).
Major Provisions
COMMENTS
Each year, approximately 185,000 Californians receive a new cancer diagnosis. Chemotherapy — medication delivered intravenously to target rapidly dividing tumor cells — is used to treat many common solid tumor cancers, including breast, ovarian, uterine, lung, and sarcomas. Chemotherapy-induced alopecia is typically temporary; hair usually begins to regrow within weeks to months after treatment ends. Chemotherapy-induced alopecia typically begins two to four weeks after the start of treatment and is consistently among the most commonly reported and distressing side effects of cancer treatment. Unlike most other side effects, hair loss is visible to others, and patients may lose control over who knows they have cancer and when. Scalp cooling works by cooling the scalp before, during, and after chemotherapy infusion to reduce the amount of drug delivered to hair follicles, thereby aiming to reduce hair loss. FDA-cleared scalp cooling systems are automated, which allows cool fluid to circulate through the cap to maintain the desired temperature for long periods of time. Manual cold caps, by contrast, are stored in freezers or with dry ice and must be swapped out by hand throughout the infusion as they warm up. The FDA-cleared scalp cooling systems covered under this bill are marketed under the names DigniCap, Paxman, and Amma. This bill would require coverage for FDA-cleared automated scalp cooling systems; manual cold caps are excluded from the bill.
California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on essential health benefits, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP's purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Premium increases. An estimated 680 additional enrollees would receive scalp cooling under the provisions of this bill, resulting in overall premiums paid by employers and enrollees increasing by an estimated $4,010,000 annually.
- Medical effectiveness. CHBRP found strong evidence that FDA-cleared automated scalp cooling devices are effective in reducing chemotherapy-induced alopecia. Some evidence suggests that scalp cooling devices may be less effective for patients with different hair types, such as Black patients with curly hair. There is strong evidence indicating that scalp cooling does not raise the risk of scalp metastasis.
- Public health impacts. CHRBP determined that approximately 333 newly covered enrollees experiencing significantly less hair loss than they otherwise would have, which may reduce distress, anxiety, and self-image impacts associated with chemotherapy-induced alopecia. The long-term trajectory of this bill may depend on several interacting factors, including the pace of utilization growth relative to per-unit pricing, and the reduction in utilization of other services like medical wigs, cold caps, or mental health services that were not directly modeled in this analysis.
Office of Health Care Affordability (OHCA) cost targets. OHCA was established in 2022 in response to widespread cost-related access challenges across California. According to the California Health Care Foundation (CHCF), over half of Californians say they skip or delay health care due to costs. OHCA collects, analyzes, and publicly reports data on total health care expenditures and enforces spending targets. OHCA’s spending targets are intended to reduce excess spending and slow health care spending growth. In April of 2024, OHCA approved a statewide cost growth target of 3.5% starting in 2025 and phasing down to 3% by 2029. Health care entities, including health plans and insurers, are subject to the statewide spending target and are subject to progressive enforcement if the entity's costs exceed the target. Some entities have raised concerns that new legislative insurance mandates will make it difficult for them to meet the established cost growth target.
Current law does not explicitly require OHCA to adjust the cost growth targets based on changes to state policy, such as insurance mandates, that may increase spending. However, it does require OHCA to consider state benefit mandates in its development and enforcement of cost growth targets. Specifically, when establishing cost growth target methodology, OHCA is required to review relevant state policy changes impacting covered benefits, provider reimbursement, and costs, among other factors. In addition, in enforcing cost growth targets, OHCA is required to consider factors that contribute to spending in excess of the applicable target, and the extent to which each entity has control over the applicable components of its cost targets.
According to the Author
This bill is a critical step toward improving supportive cancer care and ensuring that patients receiving chemotherapy can have access to medically necessary treatment. The author continues that scalp cooling is an FDA cleared, evidence-based therapy for chemotherapy-induced hair loss – yet insurance coverage remains inconsistent and unpredictable. The author notes that this leaves many patients with significant out-of-pocket costs during an already difficult time. The author concludes that by requiring California health plans and health insurers to cover scalp cooling when prescribed by a provider, this bill will remove major financial barriers and support patients’ mental health by reducing treatment-related distress.
Arguments in Support
Cooler Heads Care writes in support of this bill, stating that hair loss is not simply cosmetic; for many patients, it represents loss of privacy, identity, and control during an already vulnerable time. Cooler Heads Care continues that in modern oncology care, there are supportive remedies available for nearly every major chemotherapy side effect, from medications that address nausea and vomiting to therapies that manage pain and fatigue, hair loss should be no different. Cooler Heads Care continues that demand for scalp cooling continues to increase as awareness expands and clinicians seek supportive care solutions that treat the whole person. Cooler Heads Care notes that despite its demonstrated benefit, cost for scalp cooling remains a barrier for many patients. Cooler Heads Care concludes that insurance coverage would significantly expand equitable access, ensuring that patients are not forced to forego this supportive therapy due to financial constraints.
Arguments in Opposition
The California Association of Health Plans, Association of Life and Health Insurance Companies, and America's Health Insurance Plans oppose this bill and 10 others that mandate new benefit coverage. The opposition states that these bills will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. The opposition continues that state mandates increase premium costs for families and individuals and small business owners who cannot or do not wish to self-insure. The opposition argues that large employers, unions, small businesses, and hard-working families value their ability to shop for the right health plan – at the right price – that best fits their needs. The opposition continues that benefit mandates impose a one-size-fits-all approach to medical care and benefit design without consideration for consumer choice. The opposition states that while OHCA is working to curb healthcare costs and ensure resources are allocated in an efficient and affordable manner, adding new mandates at this pivotal moment could disrupt these efforts by driving up costs for insurers, employers, and consumers, while making it difficult for health care entities to meet the established spending target. The opposition argues that by halting new mandates, the Legislature can support OHCA's efforts of making quality health care accessible and affordable for Californians. The opposition concludes that now is the time to focus on stability and affordability for all Californians.
FISCAL COMMENTS
According to the Assembly Committee on Appropriations:
- CHBRP estimates costs to the Medi-Cal program would increase by $180,000 (General Fund (GF)), federal funds).
- CHBRP estimates this bill will increase employer premiums for health plans regulated by the Department of Managed Health Care (DMHC) in the California Public Employees Retirement System (CalPERS) by $217,000, of which some costs would be paid by enrollees and non-state employers. There would be additional state costs for the 26% of CalPERS members with health insurance policies regulated by the California Department of Insurance (CDI). The state's share of CalPERS costs would likely be around $150,000 (GF).
- CDI estimates costs of $6,000 in fiscal year (FY) 2026-27 and $18,000 in FY 2027-28 to review insurance policy forms (Insurance Fund).
- DMHC anticipates minor and absorbable costs.
- CHBRP estimates this bill will increase overall premiums paid by employers and enrollees by $4 million annually.
VOTES
ASM HEALTH: 14-0-2
YES: Bonta, Addis, Aguiar-Curry, Ahrens, Caloza, Carrillo, Mark González, Johnson, Patel, Patterson, Rogers, Schiavo, Sharp-Collins, Stefani
ABS, ABST OR NV: Chen, Sanchez
ASM APPROPRIATIONS: 12-0-3
YES: Wicks, Hoover, Aguiar-Curry, Calderon, Caloza, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache
ABS, ABST OR NV: Dixon, Ta, Tangipa
UPDATED
VERSION: February 2, 2026
CONSULTANT: Riana King / HEALTH / (916) 319-2097 FN: 0002882
Date of Hearing: May 6, 2026
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 1682
Author:(Hart) – As Introduced Ver:February 2, 2026
Policy Committee: | Health | Vote: | 14 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires a health plan, health insurance policy, and the Medi-Cal program cover scalp cooling, as prescribed by a health care provider in connection with chemotherapy or for persons with cancer.
Specifically, this bill:
- Requires cost sharing (copayments, coinsurance, or deductibles) for scalp cooling to be no less favorable to an enrollee than cost sharing for oncology supportive care services.
- Defines “scalp cooling” as the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss) and specifies that scalp cooling does not include non-FDA-cleared products.
FISCAL EFFECT:
- The California Health Benefits Review Program (CHBRP) estimates costs to the Medi-Cal program would increase by $180,000 (General Fund (GF)), federal funds).
- CHBRP estimates this bill will increase employer premiums for health plans regulated by the Department of Managed Health Care (DMHC)) in the California Public Employees Retirement System (CalPERS) by $217,000, of which some costs would be paid by enrollees and non-state employers. There would be additional state costs for the 26% of CalPERS members with health insurance policies regulated by the Department of Insurance (CDI). The state’s share of CalPERS costs would likely be around $150,000 (GF).
- CDI estimates costs of $6,000 in fiscal year (FY) 2026-27 and $18,000 in FY 2027-28 to review insurance policy forms (Insurance Fund).
- DMHC anticipates minor and absorbable costs.
CHBRP estimates this bill will increase overall premiums paid by employers and enrollees by $4 million annually.
The Legislative Analyst’s Office recently warned of General Fund structural deficits of around $35 billion per year in FY 2027-28 and ongoing.
COMMENTS:
- Purpose. This bill is sponsored by three individuals. According to the author:
[This bill] is a critical step toward improving supportive cancer care and ensuring that patients receiving chemotherapy can have access to medically necessary treatment. Scalp cooling is an FDA-cleared, evidence-based therapy, for chemotherapy-induced hair loss. However, insurance coverage remains inconsistent and unpredictable. This leaves many patients with significant out-of-pocket costs during an already difficult time. By requiring California health plans and health insurers to cover scalp cooling when prescribed by a provider, [this bill] will remove major financial barriers and support patients’ mental health by reducing treatment-related distress.
- Background. Chemotherapy can cause alopecia typically two to four weeks after the start of treatment and is consistently among the most commonly reported and distressing side effects of cancer treatment. Hair usually begins to regrow weeks to months after treatment ends. Unlike most other side effects, hair loss is visible to others, and patients may lose control over who knows they have cancer. Scalp cooling works by cooling the scalp before, during, and after chemotherapy infusion to reduce the amount of drug delivered to hair follicles. FDA-cleared scalp cooling systems are automated, which allows cool fluid to circulate through a cap worn on the scalp to maintain the desired temperature for long periods of time. Manual cold caps, by contrast, are stored in freezers or with dry ice and must be swapped out by hand throughout the infusion as they warm up. CHBRP found strong evidence that FDA-cleared automated scalp cooling devices are effective in reducing chemotherapy-induced alopecia. Some evidence suggests that scalp cooling devices may be less effective for patients with different hair types, such as Black patients with curly hair.
CHRBP estimates this bill would result in approximately 333 newly covered enrollees experiencing significantly less hair loss than they otherwise would, which may reduce distress, anxiety, and self-image effects associated with chemotherapy-induced alopecia. - Opposition. The California Association of Health Plans, Association of Life and Health Insurance Companies, and America’s Health Insurance Plans oppose this bill and 10 others that mandate new benefit coverage, stating these bills will increase costs, reduce choice and competition, and further incentivize some employers and individuals to avoid state regulation by seeking alternative coverage options, among other arguments.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 21, 2026
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 1682
Author:(Hart) – As Introduced Ver:February 2, 2026
SUBJECT: Health care coverage: scalp cooling.
SUMMARY: Requires a health plan, health insurer, and the Medi-Cal program, to provide coverage for scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer. Requires cost-sharing for scalp cooling to be no less favorable to an enrollee than cost-sharing for oncology supportive care services. Defines “scalp cooling” as the use of a medical device or system cleared by the federal Food and Drug Administration (FDA) applied to the scalp before, during, or after the administration of chemotherapy to reduce the incidence or severity of chemotherapy-induced alopecia (hair loss).
EXISTING LAW:
- Establishes the Department Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and California Department of Insurance (CDI) to regulate health insurers. [Health and Safety Code (HSC) § 1340, et seq. and Insurance Code (INS) § 106, et seq.]
- Establishes the Medi-Cal Program, administered by the Department of Health Care Services (DHCS), to provide comprehensive health benefits to low-income individuals who meet specified eligibility criteria. [Welfare and Institutions Code (WIC) § 14000, et seq.]
- Establishes California's Essential Health Benefit (EHB) benchmark under the federal Patient Protection and Affordable Care Act (ACA) as the Kaiser Small Group Health Maintenance Organization contract. Establishes existing California health insurance mandates and the 10 ACA mandated benefits. [HSC § 1367.005 and INS § 10112.27]
- Specifies EHBs in the following 10 categories: ambulatory patient services; emergency services; hospitalization; maternity and newborn care; mental health and substance use disorder services; prescription drugs; rehabilitative and habilitative services and devices; laboratory services; preventive and wellness services and chronic disease management; and, pediatric services, including oral and vision care. [HSC § 1367.005 and INS § 10112.27]
- Defines “basic health care services” as all of the following:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system; and,
- Hospice care. [HSC § 1345]
- Establishes the California Health Care Quality and Affordability Act, which creates the Office of Health Care Affordability (OHCA) within the Department of Health Care Access and Information (HCAI). Identifies OHCA’s three primary responsibilities: managing spending targets, monitoring system performance, and assessing market consolidation. Requires OHCA to collect, analyze, and publicly report data on total health care expenditures, and enforce spending targets set by a Health Care Affordability Board (Board). [HSC § 127500, et seq.]
FISCAL EFFECT: Unknown. This bill has not been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, this bill is a critical step toward improving supportive cancer care and ensuring that patients receiving chemotherapy can have access to medically necessary treatment. The author continues that scalp cooling is an FDA cleared, evidence-based therapy for chemotherapy-induced hair loss – yet insurance coverage remains inconsistent and unpredictable. The author notes that this leaves many patients with significant out-of-pocket costs during an already difficult time. The author concludes that by requiring California health plans and health insurers to cover scalp cooling when prescribed by a provider, this bill will remove major financial barriers and support patients’ mental health by reducing treatment-related distress.
- BACKGROUND. Each year, approximately 185,000 Californians receive a new cancer diagnosis. Chemotherapy — medication delivered intravenously to target rapidly dividing tumor cells — is used to treat many common solid tumor cancers, including breast, ovarian, uterine, lung, and sarcomas. Chemotherapy-induced alopecia is typically temporary; hair usually begins to regrow within weeks to months after treatment ends. Chemotherapy-induced alopecia typically begins 2 to 4 weeks after the start of treatment and is consistently among the most commonly reported and distressing side effects of cancer treatment. Unlike most other side effects, hair loss is visible to others, and patients may lose control over who knows they have cancer and when. Scalp cooling works by cooling the scalp before, during, and after chemotherapy infusion to reduce the amount of drug delivered to hair follicles, thereby aiming to reduce hair loss. FDA-cleared scalp cooling systems are automated, which allows cool fluid to circulate through the cap to maintain the desired temperature for long periods of time. Manual cold caps, by contrast, are stored in freezers or with dry ice and must be swapped out by hand throughout the infusion as they warm up. The FDA-cleared scalp cooling systems covered under this bill are marketed under the names DigniCap, Paxman, and Amma. This bill would require coverage for FDA-cleared automated scalp cooling systems; manual cold caps are excluded from the bill.
- California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Premium increases. An estimated 680 additional enrollees would receive scalp cooling under the provisions of this bill, resulting in overall premiums paid by employers and enrollees increasing by an estimated $4,010,000 annually.
- Medical effectiveness. CHBRP found strong evidence that FDA-cleared automated scalp cooling devices are effective in reducing chemotherapy-induced alopecia. Some evidence suggests that scalp cooling devices may be less effective for patients with different hair types, such as Black patients with curly hair. There is strong evidence indicating that scalp cooling does not raise the risk of scalp metastasis.
- Public health impacts. CHRBP determined that approximately 333 newly covered enrollees experiencing significantly less hair loss than they otherwise would have, which may reduce distress, anxiety, and self-image impacts associated with chemotherapy-induced alopecia. The long-term trajectory of this bill may depend on several interacting factors, including the pace of utilization growth relative to per-unit pricing, and the reduction in utilization of other services like medical wigs, cold caps, or mental health services that were not directly modeled in this analysis.
- OHCA cost targets. OHCA was established in 2022 in response to widespread cost-related access challenges across California. According to the California Health Care Foundation (CHCF), over half of Californians say they skip or delay health care due to costs. OHCA collects, analyzes, and publicly reports data on total health care expenditures and enforces spending targets. OHCA’s spending targets are intended to reduce excess spending and slow health care spending growth. In April of 2024, OHCA approved a statewide cost growth target of 3.5% starting in 2025 and phasing down to 3% by 2029. Health care entities, including health plans and insurers, are subject to the statewide spending target and are subject to progressive enforcement if the entity’s costs exceed the target. Some entities have raised concerns that new legislative insurance mandates will make it difficult for them to meet the established cost growth target.
- California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
Current law does not explicitly require OHCA to adjust the cost growth targets based on changes to state policy, such as insurance mandates, that may increase spending. However, it does require OHCA to consider state benefit mandates in its development and enforcement of cost growth targets. Specifically, when establishing cost growth target methodology, OHCA is required to review relevant state policy changes impacting covered benefits, provider reimbursement, and costs, among other factors. In addition, in enforcing cost growth targets, OHCA is required to consider factors that contribute to spending in excess of the applicable target, and the extent to which each entity has control over the applicable components of its cost targets.
- SUPPORT. Cooler Heads Care writes in support of this bill, stating that hair loss is not simply cosmetic; for many patients, it represents loss of privacy, identity, and control during an already vulnerable time. Cooler Heads Care continues that in modern oncology care, there are supportive remedies available for nearly every major chemotherapy side effect, from medications that address nausea and vomiting to therapies that manage pain and fatigue, hair loss should be no different. Cooler Heads Care continues that demand for scalp cooling continues to increase as awareness expands and clinicians seek supportive care solutions that treat the whole person. Cooler Heads Care notes that despite its demonstrated benefit, cost for scalp cooling remains a barrier for many patients. Cooler Heads Care concludes that insurance coverage would significantly expand equitable access, ensuring that patients are not forced to forego this supportive therapy due to financial constraints.
- OPPOSITION. The California Association of Health Plans, Association of Life and Health Insurance Companies, and America’s Health Insurance Plans oppose this bill and 10 others that mandate new benefit coverage. The opposition states that these bills will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. The opposition continues that state mandates increase premium costs for families and individuals and small business owners who cannot or do not wish to self-insure. The opposition argues that large employers, unions, small businesses, and hard-working families value their ability to shop for the right health plan – at the right price – that best fits their needs. The opposition continues that benefit mandates impose a one-size-fits-all approach to medical care and benefit design without consideration for consumer choice. The opposition states that while OHCA is working to curb healthcare costs and ensure resources are allocated in an efficient and affordable manner, adding new mandates at this pivotal moment could disrupt these efforts by driving up costs for insurers, employers, and consumers, while making it difficult for health care entities to meet the established spending target. The opposition argues that by halting new mandates, the Legislature can support OHCA’s efforts of making quality health care accessible and affordable for Californians. The opposition concludes that now is the time to focus on stability and affordability for all Californians.
REGISTERED SUPPORT / OPPOSITION:
Support
Biocom
CenCal Health
Cooler Heads Care, Inc.
Health Access California
Paxman US Inc.
Four individuals
Opposition
America's Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Small Business Association
Analysis Prepared by: Riana King / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):